AEterna Zentaris (TSX:AEZS) Total Current Assets : C$48.79 Mil (As of Dec. 2023)

View and export this data going back to 1995. Start your Free Trial

What is AEterna Zentaris Total Current Assets?

Total current assets includes Cash, Cash Equivalents, Marketable Securities, Total Receivables, Total Inventories, and Other Current Assets. AEterna Zentaris's total current assets for the quarter that ended in Dec. 2023 was C$48.79 Mil.

AEterna Zentaris Total Current Assets Historical Data

The historical data trend for AEterna Zentaris's Total Current Assets can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

AEterna Zentaris Total Current Assets Chart

AEterna Zentaris Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Current Assets

Get a 7-Day Free Trial

14.37

35.37

90.65

75.38

48.79

AEterna Zentaris Quarterly Data
	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23
Total Current Assets	Get a 7-Day Free Trial															75.38	69.38	60.97	56.71	48.79

AEterna Zentaris Total Current Assets Calculation

Total Current Assets are the asset that can be converted to cash or used to pay current liabilities within 12 months.

AEterna Zentaris's Total Current Assets for the fiscal year that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	45.636	+	0.46	+	0.089	+	2.605
	=	48.79

AEterna Zentaris's Total Current Assets for the quarter that ended in Dec. 2023 is calculated as

Total Current Assets	=	Cash, Cash Equivalents, Marketable Securities	+	Total Receivables	+	Total Inventories	+	Other Current Assets
	=	45.636	+	0.46	+	0.089	+	2.605
	=	48.79

Total Current Assets is linked to the Current Ratio, which is the result of dividing total current assets by total current liabilities. It is frequently used as an indicator of a company's liquidity, its ability to meet short-term obligations.

Total Current Assets is also linked to Working Capital, Net working capital is calculated as Total Current Assets minus Total Current Liabilities.

AEterna Zentaris (TSX:AEZS) Total Current Assets Explanation

In Ben Graham's calculation of liquidation value, inventory is only considered worth half of its book value, and accounts receivable is considered worth 75% of its value. Therefore the liquidation value is lower than calculated from total current assets.

AEterna Zentaris's Liquidation Value for the quarter that ended in Dec. 2023 is

	Liquidation value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	45.636	-	25.249	+	0.75 * 0.09	+	0.5 * 0.089
=	20.50

AEterna Zentaris Total Current Assets Related Terms

Thank you for viewing the detailed overview of AEterna Zentaris's Total Current Assets provided by GuruFocus.com. Please click on the following links to see related term pages.

AEterna Zentaris (TSX:AEZS) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » AEterna Zentaris Inc (TSX:AEZS) » Definitions » Total Current Assets

Comparable Companies

Traded in Other Exchanges

AEZS:USA ET8:Germany

Address

222 Bay Street, Suite 3000, PO Box 53, c/o Norton Rose Fulbright Canada, LLP, Toronto, ON, CAN, M5K 1E7

Website

https://www.zentaris.com

AEterna Zentaris Inc is a biopharmaceutical company commercializing & developing therapeutics & diagnostic tests. The company's product, Macrilen (macimorelin), is the oral test indicated for the diagnosis of adult growth hormone deficiency (GHD). Macrilen is marketed in the U.S. through a license agreement with Novo Nordisk & the company receives royalties on sales. Aeterna owns all rights to macimorelin outside of the U.S. & Canada. It is leveraging the clinical success & safety profile of macimorelin to develop it for the diagnosis of child-onset GHD. The company's geographical segments include Switzerland, Ireland, Denmark, and others, of which nearly all of its revenue comes from Switzerland.